Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | PRCP | P42785 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8576390 | 1.00 | MME (0.37) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL24709572 | 0.82 | PRCP (0.32) | PRCP | |
| SCHEMBL13127956 | 0.82 | PRCP (0.32) | PRCP | |
| SCHEMBL22251624 | 0.81 | MME (0.39) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL2863541 | 0.81 | MME (0.39) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL2863543 | 0.81 | MME (0.39) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL3468812 | 0.78 | SMN1; SMN2 (0.41) | CA2CA1PRCPALDH1A1MAPT | |
| SCHEMBL15235415 | 0.78 | SIGMAR1 (0.38) | RAB9ACA2CA1PRCPALDH1A1 | |
| SCHEMBL22092480 | 0.77 | SMN1; SMN2 (0.38) | MMERAB9AACECPA1ACE2 | |
| SCHEMBL29538486 | 0.77 | CA2 (0.41) | MMECA2CA1PRCPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-10-31 | — | — | US | disclosed |
| US-5840712-A | TARGETS AND LINKERS | RECEPTAGEN CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
| US-5739287-A | BOUND ALSO TO A RECEPTOR MODULATING AGENT TO IMPEDE CELL SURFACE RECEPTOR TRAFFICKING PATHWAYS BY INHIBITING THE RECYCLING OF RECEPTORS TO THE CELL SURFACE; ANTITUMOR AND -CARCINOGENIC AGENTS; LEUKEMIA | UNIVERSITY OF WASHINGTON (US) | 1998-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | MME 479/4885RAB9A 1709/4885ACE 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.